TOP GLOVE CORP BHD-SPONS ADR Business Summary

Top Glove Corporation Bhd (TGLVY) is the world’s largest manufacturer of rubber gloves, operating a vertically integrated business model that generates revenue through the high-volume production and global distribution of medical and industrial-grade protective gear. The company’s primary business segments are categorized by material composition, with nitrile gloves accounting for approximately 50% of the product mix, followed by natural rubber (latex), surgical, and vinyl/TPE/CPE gloves. Leveraging 51 manufacturing facilities across Malaysia, Thailand, and Vietnam, Top Glove serves over 2,000 customers in 195 countries, utilizing a "T6" transformation strategy focused on AI-driven automation and cost optimization to maintain a competitive cost structure. In the global landscape, Top Glove maintains its position as the volume leader, competing directly with Malaysian peers Hartalega Holdings and Kossan Rubber Industries, as well as Chinese challenger Intco Medical. While rivals like Hartalega specialize in high-end nitrile technology, Top Glove’s massive scale and ability to switch production lines between nitrile and natural rubber provide a unique competitive advantage in managing raw material volatility and serving diverse emerging markets. The company is led by Founder and Executive Chairman Tan Sri Dr. Lim Wee Chai, who established the firm in 1991 and holds a PhD in Management. As of April 2026, the group transitioned to a dual leadership structure with Ng Yong Lin and Lim Jin Feng serving as Joint Managing Directors. Ng, a former Chief Operating Officer with 17 years of experience in manufacturing operations, oversees the group’s multi-country production ecosystem, while Lim Jin Feng, the founder’s son, brings 15 years of expertise in marketing and strategic initiatives to lead the company’s market expansion and innovation agenda. Former Managing Director Lim Cheong Guan continues to support the board as a Corporate Director, ensuring continuity in corporate governance and investor relations. The company’s institutional backing includes major global asset managers such as BlackRock and The Vanguard Group, alongside significant domestic investors like Kumpulan Wang Persaraan (KWAP), reflecting its status as a critical component of the global healthcare supply chain.